Vical Expands Deal With PMC
Naked DNA vaccine company Vical has extended its agreement with Pasteur Merieux Connaught. PMC has now exercised its rights to four of the five original vaccine targets, extended its option for the fifth target and added a sixth option, herpes zoster.
The agreement now covers the following six vaccine targets: cytomegalovirus; respiratory syncytial virus; Lyme disease; Helicobacter pylori; malaria; and herpes zoster. In return for these rights, PMC has paid two installments to Vical totalling almost $4 million.
The new terms extend the agreement which Vical originally entered into with Pasteur Merieux Serums et Vaccins in 1994, which was renewed for an additional year by PMC in October 1995 (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze